Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q1 2026 · 10-Q
Revenue$16.96M$16.96M+71.5% vs Q1 2025 Net Income-$46.66M-$46.66MN/M vs Q1 2025 EPS Diluted-$0.20-$0.20N/M vs Q1 2025 Operating Income-$44,866,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
Free Cash Flowderived-$38,721,000N/M Margins · derivedOperating margin-264.6%+107.6 pt vs Q1 2025
Net margin-275.2%+95.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end